TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00966472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + Rosuvastatin
Description: Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
Study: NCT01342510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/Magnesium
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
Study: NCT05694728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
Description: For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
Description: A 3-dose regimen administered at months 0, 2 and 6.
Study: NCT03080259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulant Diversion Prevention (SDP)
Description: provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
Study: NCT00918021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: normal dosage of olanzapine (the same dosage as on hospital ward)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01137942

Intervention type: DRUG
Intervention: clarithromycin, metronidazole, proton pump inhibitor
Description: appropriate dose of antibiotics and proton pump inhibitor
Study: NCT05751239

Intervention type: OTHER
Intervention: Questionaire
Description: All participants answered an online questionaire. Out of the 837 participants 641 were included

Intervention type: OTHER
Intervention: Questionaire
Description: All participants answered an online questionaire. Out of the 837 participants 641 were included

Intervention type: OTHER
Intervention: Questionaire
Description: All participants answered an online questionaire. Out of the 837 participants 641 were included

Intervention type: OTHER
Intervention: Questionaire
Description: All participants answered an online questionaire. Out of the 837 participants 641 were included
Study: NCT03044405

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fluid challenge
Description: Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Focused transthoracic echocardiography
Description: Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
Study: NCT01454921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evolution: Young Women Taking Charge and Growing Stronger
Description: The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evolution: Young Women Taking Charge and Growing Stronger
Description: The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
Study: NCT03492255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
Study: NCT04961034

Intervention type: PROCEDURE
Group type: OTHER
Intervention: kasai portoenterostomy
Description: surgical creation of stoma between porta hepatis and jejunal loop

Intervention type: PROCEDURE
Group type: OTHER
Intervention: kasai portoenterostomy
Description: surgical creation of stoma between porta hepatis and jejunal loop
Study: NCT01787409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03866824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of Platelet Enhanced Plasma(PRP)
Description: intra-articular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of corticosteroids
Description: intra-articular injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMI
Description: A CONTROL RMI at 1 year follow-up.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RMI
Description: A CONTROL RMI at 1 year follow-up.
Study: NCT03110497

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single application multi-fraction brachytherapy
Description: Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
Study: NCT03578341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orally Colostrum
Description: Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Orally Colostrum
Description: Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
Study: NCT02853097

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo blood collection

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03241485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: 5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline intrathecal given in the same manner as the intervention groups.
Study: NCT01974414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orally administered cedar honey
Study: NCT03390049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 Laser Treatment
Description: After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Treatment
Description: After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
Study: NCT01144897

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Acetate scan
Description: PET Acetate scans will be done to detect prostate cancer lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon-11 labeled Acetate
Description: C-11 Acetate is a radiotracer used in PET scanning
Study: NCT03470272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FB Professional LED Red light therapy
Description: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effects of Red Light LED Therapy on Body Contouring
Description: Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
Study: NCT02503956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perforated Punctal plugs
Description: Perforated punctal plugs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crawford tube insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crawford lacrimal tube
Study: NCT01287832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin dosed to achieve a trough of 15-20 microgram/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study: NCT03899246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eight Percent Topical Capsaicin
Description: See arm description
Study: NCT05668702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: crossover design
Description: The researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
Study: NCT04504994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inclusion condition
Description: cyberball game: ex- versus over-inclusion condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inclusion condition
Description: cyberball game: ex- versus over-inclusion condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inclusion condition
Description: cyberball game: ex- versus over-inclusion condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inclusion condition
Description: cyberball game: ex- versus over-inclusion condition
Study: NCT01074944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate
Description: Oral Capsule in 50 mg or 100 mg dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate
Description: Oral Capsule in 50 mg or 100 mg dosages
Study: NCT03513991

Intervention type: OTHER
Group type: OTHER
Intervention: Infant formula

Intervention type: OTHER
Group type: OTHER
Intervention: Infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Study: NCT01122186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Cognitive Behavioral Skills Training
Description: The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Attention Control
Description: During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery.
Study: NCT00052598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT02562573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI4050
Study: NCT02129322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study: NCT04552860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
Study: NCT02297399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-ascorbate 2L
Description: Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG 4L
Description: Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken.
Study: NCT01772875

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bladder lavage
Description: the bladder is rinced through the urinary catheter with the lavage solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bladder lavage
Description: the bladder is rinced through the urinary catheter with the lavage solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bladder lavage
Description: the bladder is rinced through the urinary catheter with the lavage solution

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: bladder lavage
Description: the bladder is rinced through the urinary catheter with the lavage solution
Study: NCT02432053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Study: NCT03182777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental restorative procedure
Description: Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental restorative procedure
Description: Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
Study: NCT03872687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single tufted brush with IDB
Description: Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interdental brushes
Description: Subjects in this group will only receive interdental brushes
Study: NCT01485822

Intervention type: PROCEDURE
Intervention: Trabecular Meshwork Tissue Collection
Description: A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.

Intervention type: PROCEDURE
Intervention: Trabecular Meshwork Tissue Collection
Description: A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.

Intervention type: DRUG
Intervention: Travoprost 0.004% ophthalmic solution
Study: NCT01408043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Undergo apheresis
Study: NCT03545204

Intervention type: OTHER
Group type: OTHER
Intervention: Kangaroo Mother Care Package
Description: The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Standard Care
Description: Routine Standard Care ( essential Newborn care )ENC
Study: NCT03786458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based decision aid
Description: The decision aid is then developed further process of evidence synthesis and multidisciplinary external review.